Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Noël Trochu

Showing results (1-10 of 76) with videos related to

Pageof 8
Sort By:
Presse Medicale (Paris, France : 1983)|December 10, 2023
Chronic heart failure with reduced EF: A decade of major pharmacological innovationsJean-Noël Trochu
La Revue Du Praticien|March 19, 2021
[New treatments for systolic heart failure]Jean-Noël Trochu
Bulletin De L'Academie Nationale De Medecine|April 29, 2016
[Not Available]Jean-Noël Trochu
La Revue Du Praticien|November 2, 2010
[Non-medical and non-instrumental therapy in heart failure]Anne-Laure Laprerie, Jean-Noël Trochu
Therapie|August 12, 2009
[Experience and prospects in the treatment of heart failure]Jean-Noël Trochu, Jean-Pierre Gueffet
La Revue Du Praticien|May 12, 2004
[Prevention of cardiac arrhythmias: what is the place for antiarrhythmic drugs?]Vincent Probst, Jean-Noël Trochu, Hervé Le Marec
Soins; La Revue De Reference Infirmiere|June 12, 2026
[Heart failure: the importance of a structured care pathway and shared expertise]Jean-Noël Trochu, Céline Chauveau, Julie Redureau, et al.
Journal of the American College of Cardiology|April 25, 2009
Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heartBertrand Rozec, Mortéza Erfanian, Karine Laurent, et al.
Geriatrie Et Psychologie Neuropsychiatrie Du Vieillissement|June 2, 2022
Gilles Berrut, Nicolas Piriou, Anne Sophie Boureau, et al.
British Journal of Pharmacology|September 5, 2002
Beta 3-adrenoceptor in rat aorta: molecular and biochemical characterization and signalling pathwayYohann Rautureau, Gilles Toumaniantz, Sabrina Serpillon, et al.
Pageof 8

Showing results (1-10 of 76) with videos related to

Sort By:
Pageof 8
Presse Medicale (Paris, France : 1983)|December 10, 2023
Chronic heart failure with reduced EF: A decade of major pharmacological innovationsJean-Noël Trochu
La Revue Du Praticien|March 19, 2021
[New treatments for systolic heart failure]Jean-Noël Trochu
Bulletin De L'Academie Nationale De Medecine|April 29, 2016
[Not Available]Jean-Noël Trochu
La Revue Du Praticien|November 2, 2010
[Non-medical and non-instrumental therapy in heart failure]Anne-Laure Laprerie, Jean-Noël Trochu
Therapie|August 12, 2009
[Experience and prospects in the treatment of heart failure]Jean-Noël Trochu, Jean-Pierre Gueffet
La Revue Du Praticien|May 12, 2004
[Prevention of cardiac arrhythmias: what is the place for antiarrhythmic drugs?]Vincent Probst, Jean-Noël Trochu, Hervé Le Marec
Soins; La Revue De Reference Infirmiere|June 12, 2026
[Heart failure: the importance of a structured care pathway and shared expertise]Jean-Noël Trochu, Céline Chauveau, Julie Redureau, et al.
Journal of the American College of Cardiology|April 25, 2009
Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heartBertrand Rozec, Mortéza Erfanian, Karine Laurent, et al.
Geriatrie Et Psychologie Neuropsychiatrie Du Vieillissement|June 2, 2022
Gilles Berrut, Nicolas Piriou, Anne Sophie Boureau, et al.
British Journal of Pharmacology|September 5, 2002
Beta 3-adrenoceptor in rat aorta: molecular and biochemical characterization and signalling pathwayYohann Rautureau, Gilles Toumaniantz, Sabrina Serpillon, et al.
Pageof 8